ESR1 and breast carcinoma: This result is relevant due to ER+ breast cancer tumors are hormone responsive, indicating that lupeol could exert effects on ER- tumors such as basal or triple negative, which are the most difficult mammary tumors to treat, because are unresponsive to typical hormone therapy.